Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Mirae Asset Capital Life Science was established in 2023 as a joint venture between Mirae Asset Capital and Mirae Asset Global Investments. This firm is the first and only U.S. affiliate dedicated to life-science investment within the broader Mirae Asset platform. The firm focuses on private life-science and biotechnology companies, leveraging the extensive resources and expertise of its parent organizations.
As a newly formed entity, Mirae Asset Capital Life Science operates with a fund size of $50 million, specifically targeting investments in the life sciences sector. The firm has a global reach, with a particular emphasis on North America, and aims to support portfolio companies in achieving clinical proof of concept. The team is strategically located in key biotech hubs, including Boston and San Francisco, with legal and administrative support based in New York.
Notable milestones include the launch of their inaugural fund, Mirae Asset Capital Life Science Inception I, LP, which is focused on private biotech companies from seed to Series C. The firm’s backing by Mirae Asset Financial Group provides a strong foundation for its investment activities.
Mirae Asset Capital Life Science primarily invests in companies at the Seed, Series A, Series B, and Series C stages, with a check size ranging from $1 million to $10 million. The firm has a modality-agnostic approach to therapeutics and an opportunistic stance on diagnostics. Their investment strategy emphasizes companies entering clinical trials, particularly in the life sciences sector.
The firm focuses on five core therapeutic areas: Oncology, Immunology, Cardiovascular/Metabolic, Central Nervous System/Ophthalmology, and Rare/Genetic Diseases. Additionally, there is a strong interest in digital health applications that utilize artificial intelligence and machine learning tools. This focus aligns with their investment thesis, which prioritizes companies that deliver safe and effective treatments quickly to patients.
Mirae Asset Capital Life Science seeks to generate value through clinical proof of concept and is open to seed opportunities that demonstrate a clear path to value. The firm’s investment strategy is designed to support innovative modalities while ensuring rigorous scientific and market evaluation.
Mirae Asset Capital Life Science has built a notable portfolio of companies engaged in innovative therapies across various sectors. Key portfolio companies include:
These companies reflect Mirae Asset Capital Life Science's commitment to supporting advancements in therapeutics and diagnostics, particularly in areas with significant unmet medical needs. The firm’s portfolio showcases a blend of early-stage and more established companies, indicating a strategic approach to investment in the life sciences sector.
Naveen M. Krishnan, MD, MPhil | Managing Director: Naveen leads Mirae Asset Capital Life Science, overseeing investments and strategic growth. He has nearly 20 years of experience in healthcare, spanning biomedical research, medical training, and venture capital investing.
David T. Paik, PhD | Vice President: David has a background in biochemistry and cell biology, with prior roles in healthcare investment at RTW Investments and Sazze Partners. He holds a PhD and has completed postdoctoral training at Stanford.
Thomas Suter, PhD | Associate: Thomas has a PhD in molecular biology and experience in consulting and venture capital. He has worked with L.E.K. Consulting and NuFund Venture Group, bringing valuable insights into the biotech sector.
To pitch to Mirae Asset Capital Life Science, founders should utilize the contact page at lifesci.miraeasset.com/contact or email lifesci@miraeasset.com. It is recommended to include a comprehensive overview of the business, including the clinical development plan, market analysis, and any preliminary data supporting the technology.
While specific pitch guidelines are not disclosed, clarity and conciseness in the presentation are crucial. Founders should expect a response time that may vary based on the volume of inquiries, so patience is advised. Warm introductions are beneficial but not strictly necessary.
In March 2026, Mirae Asset Capital Life Science participated in a significant merger and financing round for Candid Therapeutics, which raised over $505 million to advance its bispecific T-cell engager therapeutics for autoimmune diseases.
In April 2025, the firm was involved in a $90 million Series C financing for Attovia Therapeutics, aimed at advancing its ATTOBODY-based programs through clinical proof of concept in immune-mediated diseases.
The firm continues to highlight its investment focus and notable portfolio companies on its website, indicating active engagement in the life sciences investment landscape.
What are Mirae Asset Capital Life Science's investment criteria?
The firm primarily invests in Seed, Series A, Series B, and Series C companies, focusing on those entering clinical trials. They are modality-agnostic regarding therapeutics and opportunistic with diagnostics, with a strong interest in digital health applications utilizing AI and machine learning.
How can I pitch to Mirae Asset Capital Life Science?
Founders can reach out via their pitch email at lifesci@miraeasset.com or through their contact page at lifesci.miraeasset.com/contact. It is advisable to include a clear overview of the business model, market opportunity, and clinical development plans in the pitch.
What makes Mirae Asset Capital Life Science different from other VCs?
The firm is uniquely positioned as the first U.S. affiliate dedicated to life-science investment within the Mirae Asset platform. Their focus on clinical proof of concept and a modality-agnostic approach allows them to support a diverse range of therapeutic innovations.
What is the geographic focus of Mirae Asset Capital Life Science?
Mirae Asset Capital Life Science has a global investment strategy, with a particular emphasis on North America. This allows them to tap into key biotech hubs and leverage a broad network of resources.
What is the typical check size for investments?
The firm typically invests between $1 million and $10 million in their portfolio companies, depending on the stage and specific needs of the business.
What kind of support do portfolio companies receive post-investment?
Mirae Asset Capital Life Science leverages its global biotech network and expertise in life sciences to assist portfolio companies in navigating the complexities of drug development and achieving clinical proof of concept.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.